State Action
CCAGW Urges Oregon Senate Judiciary Committee to Oppose SB 619
SB 619 will fail to achieve its objective of protecting consumer privacy.
CCAGW Urges Minnesota House Health Finance and Policy Committee to Oppose HF 17
HF 17 would impose price controls on prescription drugs through the establishment of the Prescription Drug Affordability Review Board.
CCAGW Urges Oklahoma Senate Appropriations Committee to Support SB 118
SB 118 will allow for greater innovation and competition in Oklahoma by establishing a regulatory sandbox.
CCAGW Urges Rhode Island House Innovation, Internet, & Technology Committee to Oppose H 5745
H 5745 will fail to achieve its objective of protecting consumer privacy.
CCAGW Urges Minnesota Senate Health and Human Services Committee to Oppose SF 2123
SF 2123 will reduce the use of tobacco harm reduction products (THR), increase the purchase of tobacco products on an unregulated black market, and fail to reduce smoking.
CCAGW Urges Missouri House Fiscal Review Committee to Support HB 268
HB 268 will allow for greater innovation and competition in Missouri by establishing a regulatory sandbox.
CCAGW Urges Hawaii Senate Committee on Ways and Means to Oppose SB 974
SB 974 will fail to achieve its objective of protecting consumer privacy.
CCAGW Urges Alaska Senate Health and Social Services Committee to Support SB 8
SB 8 would repeal Alaska's outdated certificate-of-need laws.
CCAGW Urges Minnesota House Commerce Committee to Oppose HF 294
HF 294 will create price controls that distort the medical marketplace and impose burdensome restrictions that stifle innovation.
CCAGW Urges Hawaii Senate Commerce and Consumer Protection Committee to Oppose SB 974
SB 974 will fail to achieve its objective of protecting consumer privacy.
CCAGW Urges Missouri Senate Health and Welfare Committee to Support SB 204
SB 204 would repeal Missouri's outdated certificate-of-need laws.
CCAGW Urges Minnesota Senate Commerce and Consumer Protection Committee to Oppose SF 168
SF 168 would impose price controls on prescription drugs through the establishment of the Prescription Drug Affordability Review Board.
